Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Tris Acquires NextWave | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Tris Acquires NextWave

Acquisition of NextWave, a wholly owned subsidiary of Pfizer, includes two key ADHD treatments

By: Betsy Louda

, Contract Pharma

Tris Pharma announced the acquisition of NextWave Pharmaceuticals, a wholly owned subsidiary of Pfizer, including two key Attention Deficit Hyperactivity Disorder (ADHD) treatments. 

 
The acquisition further expands Tris’ portfolio of products for the treatment of patients with ADHD. The agreement includes the acquisition of Quillivant XR, the first and only marketed extended-release oral liquid methylphenidate, and QuilliChew ER, the first and only extended-release methylphenidate chewable tablet, both of which are central nervous system (CNS) stimulants approved for the treatment of ADHD.   
 
Quillivant XR and QuilliChew ER were co-developed by NextWave and Tris, utilizing Tris’ novel, proprietary LiquiXR ® platform. In 2012, Pfizer acquired NextWave, and Tris continued to manufacture both products for Pfizer, prior to and after US Food and Drug Administration (FDA) approval. 
 
“As co-developer of Quillivant XR and QuilliChew ER, we are excited to bring commercialization of these products in house and expand our ADHD portfolio,” said Ketan Mehta, president and chief executive officer, Tris. “To further support our newest acquisition, Tris is expanding our commercial footprint and building a world class medical affairs group.”    

“Our newest acquisition brings us one step closer to realizing our corporate mission, to develop and expand offerings to meet unmet needs for all patients,” said Barry K. Herman, M.D., M.M.M., Tris’ chief medical officer. “With three treatment options for patients with ADHD, Tris now offers a broad, established product portfolio with both stimulant classes in the ADHD space.”

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters